Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

The study enrolled 52 DME patients with poor vision despite prior anti-VEGF treatment and was randomized equally to receive either 10 μg UBX1325 or 2 mg of REGN’s Eylea. UBX1325 is UNITY ...

Atea had been evaluating a 2-mg dose of sozinibercept every four or eight weeks in combination with Regeneron’s blockbuster VEGF inhibitor Eylea in patients with wet age-related macular ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...